Originalien 1 2 Z Rheumatol 2018 · 77:421–428 S.-C. Bae ·Y. H.Lee https://doi.org/10.1007/s00393-017-0292-6 Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, Republic of Published online: 21 March 2017 Korea © Springer-Verlag Berlin Heidelberg 2017 Division of Rheumatology, Department of Internal Medicine, Korea University Anam Hospital, Korea University College of Medicine, Seoul, Republic of Korea Redaktion U. Müller-Ladner, Bad Nauheim U. Lange, Bad Nauheim Comparative eﬃcacy and tolerability of sarilumab 150 and 200 mg in patients with active rheumatoid arthritis A Bayesian network meta-analysis of randomized controlled trials Introduction Rheumatoid arthritis (RA) is a systemic autoimmune disease characterized by chronic synovial joint inﬂammation, which leads to disability and loss of quality of life [6, 15]. Interleukin-6 (IL- 6) is a multifunctional cytokine involved in inﬂammatory responses and in the modulation of immune responses, in- cluding B cell and T cell diﬀerentiation . IL-6 is overexpressed in the af- fected tissues of RA patients and elevated levels of IL-6 in the serum andsynovial ﬂuidare associated with synovitis, systemic inﬂammation, bone metabolism, and joint destruction . A humanized, anti-human IL-6 receptor monoclonal antibody, tocilizumab, was designed to block IL-6 signaling and has been used as an eﬀective therapeutic agent for
Zeitschrift für Rheumatologie – Springer Journals
Published: Mar 21, 2017
It’s your single place to instantly
discover and read the research
that matters to you.
Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.
All for just $49/month
Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly
Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.
Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.
Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.
All the latest content is available, no embargo periods.
“Hi guys, I cannot tell you how much I love this resource. Incredible. I really believe you've hit the nail on the head with this site in regards to solving the research-purchase issue.”Daniel C.
“Whoa! It’s like Spotify but for academic articles.”@Phil_Robichaud
“I must say, @deepdyve is a fabulous solution to the independent researcher's problem of #access to #information.”@deepthiw
“My last article couldn't be possible without the platform @deepdyve that makes journal papers cheaper.”@JoseServera